Avenue Therapeutics Inc Financials

ATXI

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Avenue Therapeutics Inc (ATXI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATXI FY2025 2026-05-08

Avenue Therapeutics runs as a cash-funded development platform, with spending resets driving results more than early revenue.

The drop in cash burn to -$1.8M in FY2025 from -$9.0M in FY2024 was not mainly a revenue breakthrough. It lined up with a development-spending reset: R&D fell to $1.0M from $6.6M, so the smaller loss reflects a lower spend base more than a self-funding operating model.

Even after that reset, SG&A at $3.7M still exceeded FY2025 revenue of $1.4M, so the company remains structurally dependent on outside funding rather than on sales to cover overhead. Revenue reappeared, but it has not yet changed the business from development-led spending to operating self-sufficiency.

Operating cash flow of -$1.8M was less negative than the net loss of -$2.9M, which means accounting losses are not translating into equal cash outflow. With no long-term debt and cash making up nearly all of total assets, financing pressure comes more from periodic equity raises than from debt service.

Financial Health Signals

Financial health score pending refresh

We are recalculating Avenue Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Avenue Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.63x

For every $1 of reported earnings, Avenue Therapeutics Inc generates $0.63 in operating cash flow (-$1.8M OCF vs -$2.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4M

Avenue Therapeutics Inc generated $1.4M in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$2.9M

YoY+75.0%

Avenue Therapeutics Inc reported -$2.9M in net income in fiscal year 2025. This represents an increase of 75.0% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$2.9M

YoY+10.1%

5Y CAGR-1.8%

10Y CAGR+70.2%

Avenue Therapeutics Inc held $2.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+51.0%

Avenue Therapeutics Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 51.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-219.6%

Avenue Therapeutics Inc's operating margin was -219.6% in fiscal year 2025, reflecting core business profitability.

Net Margin

-207.2%

Avenue Therapeutics Inc's net profit margin was -207.2% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-158.8%

YoY+257.8pp

5Y CAGR+59.6pp

Avenue Therapeutics Inc's ROE was -158.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 257.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.0M

YoY-84.4%

5Y CAGR-18.4%

10Y CAGR+0.8%

Avenue Therapeutics Inc invested $1.0M in research and development in fiscal year 2025. This represents a decrease of 84.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ATXI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.4M	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.0M-84.4%	$6.6M+8.4%	$6.1M+127.2%	$2.7M+115.2%	$1.3M-56.2%	$2.9M
SG&A Expenses	$3.7M-21.2%	$4.6M+11.0%	$4.2M-21.8%	$5.3M+115.2%	$2.5M+5.8%	$2.3M
Operating Income	-$3.1M+72.7%	-$11.3M	N/A	-$8.0M-115.2%	-$3.7M+28.3%	-$5.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$2K	$0	$0	$0	N/A	N/A
Net Income	-$2.9M+75.0%	-$11.7M	N/A	-$3.6M+4.8%	-$3.7M+27.6%	-$5.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	$-0.22	$-0.31

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	$0-100.0%	$1.4M	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$200K	N/A	$177K-7.8%	$192K-53.3%	$411K	N/A	$2.3M+71.0%	$1.4M
SG&A Expenses	$514K	N/A	$547K-40.2%	$915K-38.8%	$1.5M	N/A	$829K-43.3%	$1.5M
Operating Income	-$714K	N/A	-$724K-343.8%	$297K+115.6%	-$1.9M	N/A	-$3.2M-11.8%	-$2.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$695K	N/A	-$683K-303.9%	$335K+118.1%	-$1.9M	N/A	-$3.1M-14.3%	-$2.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.9M+9.7%	$2.7M+44.4%	$1.9M-73.0%	$6.8M+72.9%	$4.0M+22.0%	$3.2M
Current Assets	N/A	N/A	N/A	N/A	$4.0M+22.0%	$3.2M
Cash & Equivalents	$2.9M+10.1%	$2.6M+45.5%	$1.8M-73.4%	$6.7M+78.3%	$3.8M+20.1%	$3.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M+979.2%	-$125K-146.6%	$268K-92.5%	$3.6M+603.1%	$509K-42.6%	$886K
Current Liabilities	$1.1M+34.7%	$816K	N/A	$3.6M+603.1%	$509K-42.6%	$886K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.8M-34.5%	$2.8M+76.8%	$1.6M-59.5%	$3.9M+13.2%	$3.5M+46.3%	$2.4M
Retained Earnings	-$105.5M-2.8%	-$102.6M-12.8%	-$90.9M-12.9%	-$80.6M-4.6%	-$77.0M-5.1%	-$73.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$2.5M-15.8%	$2.9M-21.3%	$3.7M-10.5%	$4.2M+15.8%	$3.6M+34.5%	$2.7M+1.8%	$2.6M-47.4%	$5.0M
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$2.4M-15.3%	$2.9M-23.0%	$3.7M+11.5%	$3.3M-5.0%	$3.5M+35.0%	$2.6M-0.1%	$2.6M-47.2%	$4.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M+15.6%	$1.1M+554.2%	$168K+63.1%	$103K+22.6%	$84K+167.2%	-$125K-933.3%	$15K-98.7%	$1.2M
Current Liabilities	$1.3M+15.6%	$1.1M	N/A	N/A	N/A	$816K	N/A	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.2M-34.6%	$1.8M-48.5%	$3.6M-12.3%	$4.1M+15.6%	$3.5M+25.5%	$2.8M+7.2%	$2.6M-45.2%	$4.8M
Retained Earnings	-$106.2M-0.7%	-$105.5M-0.7%	-$104.8M-0.7%	-$104.1M+0.3%	-$104.4M-1.8%	-$102.6M-1.5%	-$101.0M-3.1%	-$98.0M

ATXI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M+79.7%	-$9.0M	N/A	-$7.6M-102.6%	-$3.8M+18.7%	-$4.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0+100.0%	-$3.0M	$0	N/A	-$1.0M
Financing Cash Flow	$2.1M-78.7%	$9.8M+30.7%	$7.5M-28.6%	$10.5M+140.6%	$4.4M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0-100.0%	$1.1M	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$438K+48.7%	-$854K-323.0%	$383K+317.6%	-$176K+85.2%	-$1.2M-55.2%	-$764K+73.6%	-$2.9M-28.2%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Financing Cash Flow	$0	$0	$0	$0-100.0%	$2.1M+175.2%	$761K+34.2%	$567K-85.7%	$4.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-219.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-207.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-158.8%+257.8pp	-416.6%	N/A	-91.0%+17.1pp	-108.1%+110.3pp	-218.4%
Return on Assets	-99.3%+336.8pp	-436.1%	N/A	-51.9%+42.3pp	-94.2%+64.5pp	-158.7%
Current Ratio	N/A	N/A	N/A	N/A	7.78+4.1	3.66
Debt-to-Equity	0.60	N/A	0.17-0.7	0.92+0.8	0.15-0.2	0.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	21.1%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	23.9%	N/A	N/A	N/A	N/A
Return on Equity	-58.0%	N/A	-19.2%-27.5pp	8.3%+61.0pp	-52.8%	N/A	-117.9%-61.3pp	-56.5%
Return on Assets	-28.2%	N/A	-18.3%-26.4pp	8.1%+59.6pp	-51.5%	N/A	-117.2%-63.2pp	-54.0%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	1.06+0.5	0.60+0.6	0.05+0.0	0.030.0	0.02	N/A	0.01-0.2	0.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Restart Life NMLSF

$3.5M

Mosaic Immunoengineering Inc CPMV

$4.9M

Mynd Life Scienc MYNDF

$895K

Nascent Biotech NBIO

$3.3M

GREY MATTERS HEALTH INC, AGNPF

$1.7M

Frequently Asked Questions

What is Avenue Therapeutics Inc's annual revenue?

Avenue Therapeutics Inc (ATXI) reported $1.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Avenue Therapeutics Inc profitable?

No, Avenue Therapeutics Inc (ATXI) reported a net income of -$2.9M in fiscal year 2025, with a net profit margin of -207.2%.

What is Avenue Therapeutics Inc's operating margin?

Avenue Therapeutics Inc (ATXI) had an operating margin of -219.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Avenue Therapeutics Inc's net profit margin?

Avenue Therapeutics Inc (ATXI) had a net profit margin of -207.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Avenue Therapeutics Inc's return on equity (ROE)?

Avenue Therapeutics Inc (ATXI) has a return on equity of -158.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Avenue Therapeutics Inc's operating cash flow?

Avenue Therapeutics Inc (ATXI) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Avenue Therapeutics Inc's total assets?

Avenue Therapeutics Inc (ATXI) had $2.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Avenue Therapeutics Inc spend on research and development?

Avenue Therapeutics Inc (ATXI) invested $1.0M in research and development during fiscal year 2025.

How many shares does Avenue Therapeutics Inc have outstanding?

Avenue Therapeutics Inc (ATXI) had 3M shares outstanding as of fiscal year 2025.

What is Avenue Therapeutics Inc's debt-to-equity ratio?

Avenue Therapeutics Inc (ATXI) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avenue Therapeutics Inc's return on assets (ROA)?

Avenue Therapeutics Inc (ATXI) had a return on assets of -99.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avenue Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Avenue Therapeutics Inc (ATXI) had $2.9M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Avenue Therapeutics Inc's Piotroski F-Score?

Avenue Therapeutics Inc (ATXI) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avenue Therapeutics Inc's earnings high quality?

Avenue Therapeutics Inc (ATXI) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.